To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

Phase 3 Terminated 177 enrolled Incyte Corporation

RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of the study is to compare the efficacy and safety of parsaclisib when combined with ruxolitinb versus placebo combined with ruxolitinib in participants with myelofibrosis who have suboptimal response while receiving ruxolitinib monotherapy.

Timeline

Start: 2021-05-26
Primary completion: 2023-08-16
Completion: 2024-08-21

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Parsaclisib	Small molecule	—	Oral
Background	Ruxolitinib	Small molecule	—	Oral

To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

Summary

Timeline

Drugs

Indications